Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEACON: Bardoxolone Methyl in Stage 4 Chronic Kidney Disease with Type 2 Diabetes
2010-022297-14Phase 3Terminated
- Sponsor
- Reata Pharmaceuticals
- Start
- Jul 2011
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) comparing bardoxolone methyl with placebo (2 arms). Primary endpoint: Primary composite endpoint. Started Jul 2011; status: terminated.
02
Drugs
bardoxolone methyl
03
Conditions
chronic kidney disease (CKD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2010-022297-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022297-14.